GHO announce €660 million ﬁnal close of GHO Capital Fund I LP at hard cap
Rede Partners is pleased to have advised GHO Capital on its €660 million fundraising for its inaugural fund, GHO Capital Fund I LP, at its hard cap and considerably above its target of €500 million.
GHO Capital, the European specialist investor in healthcare, announced the successful final close for GHO Capital Fund I LP, a €660 million private equity fund which has been raised to seize the highly attractive and underpenetrated investment opportunity in European healthcare.
GHO Capital Fund I LP (“the Fund”) was significantly oversubscribed, exceeding its target of €500 million through strong support from a global investor base including leading pension funds, sovereign wealth funds, asset managers, insurance companies, fund of funds, family offices and high net worth individuals.
The Fund started investing in October 2015 and has made five investments to date: DNA Diagnostics Center, a leading DNA testing company focused on the development of innovative genetic testing products and services; Quotient Clinical, a provider of outsourced, early-stage drug development services to the pharmaceutical industry; Envision Pharma Group, a leading Medical Affairs-focused scientific communications and technology solutions provider; VISUfarma, a pan-European ophthalmic specialty pharmaceutical company; and Caprion Biosciences, the leading provider of proteomics and immune monitoring services to the pharmaceutical and biotechnology industry.
With a dedicated healthcare team of 10 investment professionals, GHO Capital’s complementary skill set combines traditional private equity and investment banking expertise with proven industrial capabilities. Backed by a global network of experts, and with a long-standing history of investment, transaction execution and senior operational roles in healthcare companies, GHO Capital is well-positioned to help ambitious management teams to deliver growth.